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OBJECTIVE: To assess the effectiveness of healthcare team guidance in the implementation of a glycemic
control protocol in the non-intensive care unit of a cardiology hospital.
METHODS: This was a randomized clinical trial comparing 9 months of intensive guidance by a healthcare team
on a protocol for diabetes care (Intervention Group, n = 95) with 9 months of standard care (Control Group,
n = 87). Clinicaltrials.gov: NCT01154413.
RESULTS: The mean age of the patients was 61.7¡10 years, and the mean glycated hemoglobin level was
71¡23 mmol/mol (8.7¡2.1%). The mean capillary glycemia during hospitalization was similar between the
groups (9.8¡2.9 and 9.1¡2.4 mmol/l for the Intervention Group and Control Group, respectively, p= 0.078).
The number of hypoglycemic episodes (p= 0.77), hyperglycemic episodes (47 vs. 50 in the Intervention Group
and Control Group, p= 0.35, respectively), and the length of stay in the hospital were similar between the
groups (p= 0.64). The amount of regular insulin administered was 0 (0–10) IU in the Intervention Group and 28
(7–56) IU in the Control Group (p,0.001), and the amount of NPH insulin administered was similar between the
groups (p= 0.16).
CONCLUSIONS: While guidance on a glycemic control protocol given by a healthcare team resulted in a
modification of the therapeutic strategy, no changes in glycemic control, frequency of episodes of
hypoglycemia and hyperglycemia, or hospitalization duration were observed.
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& INTRODUCTION
Diabetes mellitus, a highly prevalent disease character-
ized by sustained hyperglycemia and chronic complications,
leads to considerable morbidity and mortality (1). In the
course of the disease, patients often need to be hospitalized
because of infections, acute coronary syndrome, percuta-
neous/surgical coronary revascularization, stroke, or com-
plications of peripheral vascular disease, which are
frequently accompanied by worsening hyperglycemia, a
predictor of poor outcomes (e.g., prolonged hospital stay,
disability after hospital discharge, and death) (2,3).
Intensive glycemic control through continuous intrave-
nous insulin infusions has been related to better outcomes in
hospitalized patients with diabetes submitted to cardiac
surgical procedures (4,5) and after myocardial infarction (6).
Glycemic control through subcutaneous insulin regimens
can also reduce the frequency of adverse outcomes in adult
patients with diabetes that are admitted to general surgical
wards (7). However, outside these situations, diabetes
management is often not the primary focus during
hospitalization and is usually considered less important
compared with the condition that led to admission (8).
Although sliding-scale regular insulin (SSI) regimens are
criticized by specialists because of the associated glucose
instability and increased frequency of hypoglycemic events
when administered to non-intensive care patients, they are
frequently used. Reviews and guidelines strongly suggest
that SSI regimens should be avoided (9–11) because the use
of these regimens alone cannot control blood sugar levels in
many patients (12), and they are less efficient than basal-
bolus insulin therapy in reducing hypoglycemia and
achieving glycemic control (13,14).
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However, educating healthcare professionals on protocols
for ideally controlling blood glucose levels in hospitalized
patients has only been tested in a few studies, and most of
these studies were not well designed. Baldwin et al. (15)
described a case of successful education delivered by a
healthcare team regarding the implementation of a diabetes
treatment protocol; however, a historical control group was
used for comparison. The aim of this study was to evaluate
whether providing guidance to a healthcare team respon-
sible for patients with diabetes hospitalized in a non-
intensive care unit of a cardiology hospital (with emphasis
on the implementation of a glycemic control protocol) could
improve glycemic control, reduce the frequency of hypo-
and hyperglycemic episodes, and reduce the length of stay
in the hospital.
& RESEARCH DESIGN AND METHODS
Study design: The intervention program was assessed in a
randomized controlled trial developed in a non-intensive
care unit of a cardiology hospital.
Eligibility criteria: All in-patients with type 2 diabetes
consecutively admitted to a clinical ward at our institution
fromDecember 2007 toMay 2009were eligible for enrollment.
Inclusion criteria included an age over 18 years and a personal
history of type 2 diabetes mellitus (defined as an onset of
diabetes after the age of 40 years, initial treatment with diet
modification and/or oral anti-diabetic medication, current
use of any anti-diabetic medication, fasting plasma glucose
$7.0 mmol/l, or a casual glucose level .11.1 mmol/l) (16).
Exclusion criteria included known malignant neoplasia,
hemodialysis, use of corticosteroids or immunosuppressants,
cognitive neurological sequelae, an expected hospital stay of
fewer than 72 hours, transfer from an intensive care unit using
intravenous insulin regimens, or cases in which the physician
or the patient did not agree with the treatment protocol.
The study was conducted in accordance with the
Guidelines and Standards Regulating Research Involving
Human Subjects and was approved by the Research and
Ethics Committee of Instituto de Cardiologia/Fundac¸a˜o
Universita´ria de Cardiologia. Written informed consent was
obtained from each patient prior to randomization.
The sample size calculation was based on a difference in
glycemia of 20 mg/dl between the intervention (IG) and
control (CG) groups at the end of the hospitalization period.
The total number of patients in each group was 93, based on
an a of 0.05 and a power of 0.80 (b= 0.20).
Study protocol
The patients were randomly assigned to the IG or CG.
Randomization was performed using a computerized
process to generate random numbers. It was performed in
three-month blocks for each intervention period, comprising
9 months for the CG and 9 months for the IG. The trial was
registered as clinical trial number (NCT) 01154413.
Patients in the IG were treated by medical and nursing
professionals who were previously instructed in the use of a
protocol for diabetes management during hospitalization
that was based on current guidelines and local issues (9). This
systematic guidance program consisted of the following
steps: 1) Distribution of the protocol, which described the
actions to be taken based on intercurrent diseases presented
by the patients to all members of the team; 2) Monthly
meetings to review and discuss how the professionals should
act in consonance with the protocol; 3) Display of reminders
on the computer screen every time a physician prescribes
blood glucose testing, insulin, or an anti-diabetic medication;
4)Weekly in-service guidance sessions to solve questions that
may arise among the healthcare professionals, with indivi-
dual case discussion if necessary; 5) Distribution of pocket
guides, including a summary of the protocol (Figure 1); and
6) Attachment of informative labels to the chart of each
patient enrolled in the study.
Patients in the CG group were treated according to the
decisions made by healthcare professionals who received no
guidance on the protocols for treating hospitalized diabetic
patients. The healthcare team decided which monitoring
methods and drug treatments for diabetes were to be used
and the frequency at which monitoring would be pre-
scribed, as well as the use of SSI regimens based on capillary
glycemia readings, as desired.
Three nurses and one endocrinologist (B.D.S.) at the
institution were responsible for the guidance of the
healthcare professionals, which involved reviewing and
discussing issues associated with the patients’ cases. This
team was responsible for the systematic guidance of
members of the clinical staff who worked directly with the
patients admitted to the selected unit during the period of
intervention and data collection. The clinical care staff was
composed of 4 nurses, 20 nursing technicians, 6 staff
physicians, and 15 medical residents, and the staff was the
same for both the CG and IG groups. The clinical unit where
the study was conducted usually had 50 inpatients,
approximately 15% of whom had diabetes. All patients
were prescribed a low-fat, low-carb diet (16).
All patients were invited to answer a structured ques-
tionnaire containing questions about clinical and demographic
characteristics, history of the present illness, co-morbidities,
previous glycemic control, current anti-diabetic treatment, and
duration of diabetes. Anthropometric variables (weight,
height, body mass index, and waist circumference), blood
pressure, and heart rate were obtained. The results of a
biochemical evaluation, which was requested by the attending
physician on admission or by the researchers during the first
48 hours of admission, were also recorded and included
glycated hemoglobin, fasting plasma glucose, creatinine, and a
routine urinalysis.
Glycemia was checked and recorded (capillary samples,
reagent strips- Advantage, Roche, Lima, Peru) before each
meal in the IG group as described in the protocol (Figure 1)
and as prescribed by the attending physician in the CG group.
Glycemia was also checked in both groups when the patients
complained of symptoms that could be related to hypogly-
cemia. Throughout hospitalization, the following clinical
events were observed and recorded: infections, surgeries,
stroke, acute myocardial infarction, angina, death, hypogly-
cemia, and hyperglycemia. Hypoglycemia was defined as a
blood glucose level lower than 3.8 mmol/l, irrespective of the
presence or absence of symptoms. Severe hypoglycemia was
defined as a blood glucose level lower than 3.8 mmol/l in a
patient unable or unwilling, because of neuroglycopenia, to
take carbohydrates orally (17). Hyperglycemiawas defined as
a blood glucose level higher than 13.8 mmol/l, irrespective of
the presence or absence of symptoms.
Outcome measures
The primary endpoint was improvement in glycemic
control (fasting plasma glucose at the end of hospitalization).
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Secondary outcomes included the number of hypoglycemia
and hyperglycemia episodes during hospitalization, period
of hospitalization, frequency of events potentially related to
diabetes (infections, stroke, acute myocardial infarction,
angina, or death), number of glucose sachets needed for
hypoglycemic episodes, number of capillary glycemia assess-
ments, doses/number of NPH and regular insulin injections,
and use of SSI regimens during the hospitalization. These
endpoints were assessed during hospitalization through
analyses of medical and hospital infection control records.
Patients were followed for the entire hospital stay.
Statistical analysis
Categorical data are presented as frequencies, and their
differences were analyzed using the chi-square test.
Quantitative data with normal distributions are presented
as the means ¡ SD, and their differences were analyzed
using Student’s t test. Nonparametric variables are pre-
sented as the median ¡ interquartile range (IQR) (P25-P75)
and were analyzed using the Mann-Whitney test. Analysis
of covariance was used to adjust the data (glycemia) for
baseline HbA1c and plasma glucose. All tests followed the
principle of intention to treat. Differences were considered
significant for a two-tailed p-value ,0.05. Data were
analyzed using SPSS statistics software (version 19.0; SPSS,
Inc., Chicago, IL).
& RESULTS
A total of 720 patients with type 2 diabetes were admitted
between December 2007 and May 2009; 182 patients met the
inclusion criteria and were randomized into the IG (87
Figure 1 - The diabetes management protocol. NPO: from Latin, Nil per os, which means nothing through the mouth.
Algorithm for the treatment of patients with type 2 diabetes in non-intensive care units.
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patients) or CG (95 patients) (Figure 2). After randomization,
5 patients died (3 from the IG and 2 from the CG) due to
clinical complications or infections unrelated to the research
protocol. All patients were followed from admission until
discharge.
The baseline characteristics of the groups were similar
(Table 1). The mean age was 61.7¡10.2 years; 61% were
women; the fasting plasma glucose level at the time of
admission was 8.5¡3.5 mmol/l; the glycated hemoglobin
level was 71¡23 mmol/mol (8.7¡2.1%); and the duration
of diabetes was 96.0 (24.0–171.0) months. Most patients
(83.5%) were taking anti-diabetic agents, the most common
of which were metformin (52.7%) and insulin (33.5%).
The primary and secondary outcomes are presented in
Table 2. The primary outcome (improvement in glycemic
control as evaluated by fasting plasma glucose at the end of
hospitalization) was not different between the groups
(p=0.21, corrected for baseline plasma glucose, and p=0.52,
corrected for baseline HbA1c). The frequencies of hypogly-
cemic and hyperglycemic episodes were also similar between
the groups (p=0.77 and p=0.35, respectively). On average,
24.3¡16 capillary glycemia assessments were performed per
patient (23.6¡15 in the IG and 25.2¡16.5 in the CG; p=0.50).
Regular insulin was prescribed for 108 (59.3%) patients, with
a greater frequency in the CG compared with the IG (p,0.01);
NPH insulin was prescribed for 65 (37.7%) patients, with no
difference in prescription frequency between the groups
(p=0.23). A total of 40 (42.1%) and 73 (83.9%) doses of regular
insulin were administered to the IG and CG patients,
respectively (p,0.01), and 38 (40%) and 25 (28.7%) doses of
NPH insulin were administered to the IG and CG patients,
respectively (p=0.15). The amount of insulin, expressed in
units administered, was 0 (0–10) IU and 28 (7–56) IU for the
IG and CG patients (regular insulin, p,0.01), respectively,
and 0 (0–114) and 0 (0–52) for the IG and CG patients (NPH
insulin, p=0.17), respectively. These findings show that 55
(57.9%) and 14 (16.1%) patients in the IG and CG,
respectively, did not receive regular insulin, and 57 (60.0%)
and 62 (71.3%) patients in the IG and CG groups, respectively,
did not receive NPH insulin. Sliding scales of regular insulin
based on capillary glycemia were usedmore frequently in the
CG (81.6%) than in the IG (2.1%, p,0.01). The occurrence of
clinical and cardiovascular events during hospitalization was
similar between the two groups, as was the number of deaths.
The mean duration of hospitalization was 6 (4–10) days,
which was similar between the groups (p=0.64).
As shown in Figure 3, panel A, a trend toward a reduction
in the mean capillary glycemia was observed during the
first week of hospitalization in both patient groups.
However, the mean capillary glycemia during hospitaliza-
tion was not different between the groups (p= 0.08). After
adjustment for baseline HbA1c and plasma glucose, the
mean capillary glycemia was also not different between the
groups (p=0.52 and p= 0.21, respectively). To attempt to
identify any carryover effect, which was not observed, the
same analysis was performed and is shown for each 3-
month evaluation in Figure 3, panel B.
& DISCUSSION
In this randomized controlled trial, we investigated attempts
to modify diabetes care through guidance of the healthcare
Figure 2 - Flow chart of patient randomization.
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Table 1 - Baseline clinical characteristics of the patients.
Clinical Variables Control Group (n =87) Intervention Group (n=95) p- value
Age (years) 60¡10 63¡11 0.43
Female gender 58 (66.7) 53 (55.8) 0.17
Caucasian 75 (86.2) 82 (86.3) 1.00
Schooling (years) 4.0 (3.0–8.0) 5.0 (2.0–7.0) 0.68
Weight (kg) 76.6¡16.7 74.6¡14.6 0.39
Body mass index (kg/m2) 29.8¡5.4 28.4¡5.2 0.08
Systolic blood pressure (mmHg) 127.9¡23.8 132.6¡21.3 0.16
Diastolic blood pressure (mmHg) 78.5¡14.5 79.5¡11.3 0.74
HbA1c (mmol/mol and %) 75¡25 (9.0¡2.1) 68¡21 (8.4¡1.9) 0.04
Creatinine (mmol/mol) 79¡35 88¡35 0.44
Admission fasting plasma glucose (mmol/l) 8.9¡3.7 8.2¡3.2 0.47
Clinical comorbidities
Hypertension 81 (93.1) 80 (84.2) 0.10
Dyslipidemia 51 (58.6) 60 (63.2) 0.63
Smoking 49 (56.3) 53 (55.8) 1.00
Peripheral vascular disease 21 (24.1) 19 (20) 0.62
Family history of ischemic heart disease 57 (65.5) 58 (61.1) 0.63
Family history of diabetes 50 (57.5) 64 (67.4) 0.22
Heart failure 36 (41.4) 35 (36.8) 0.63
Acute myocardial infarction 45 (51.7) 43 (45.3) 0.47
Percutaneous coronary revascularization 36 (41.4) 37 (38.9) 0.85
Coronary artery bypass graft 11 (12.6) 16 (16.8) 0.55
Cardiovascular medications 83 (95.4) 93 (97.9) 0.59
ACEI 78 (89.7) 83 (87.4) 0.63
Diuretic 46 (52.9) 45 (47.4) 0.45
ASA 69 (79.3) 85 (89.5) 0.05
Statins 56 (64.4) 74 (77.9) 0.04
Beta-blocker 69 (79.3) 83 (87.4) 0.14
Diabetes medications 72 (82.8) 80 (84.2) 0.94
Metformin 50 (57.5) 46 (48.4) 0.28
Sulfonylureas 34 (39.1) 29 (30.5) 0.29
Regular insulin (IU/day) 2 (2.3) 0 (0.0) 0.43
NPH insulin (IU/day) 27 (31.0) 34 (35.8) 0.60
Diabetes duration (months) 120 (24–192) 84 (24–132) 0.35
Continuous variables are expressed as the means ¡ standard deviation and the median (P25-P75). Categorical variables are expressed as absolute
frequency (n) and relative frequency (%). The chi-square test, Student’s t test, and Mann-Whitney test were used. HbA1c: glycated hemoglobin; ACEI:
angiotensin-converting enzyme inhibitor; ASA: acetylsalicylic acid. Reference levels: HbA1c,,7.0%; creatinine, 44.2–106 mmol/l (0.50–1.20 mg/dl); plasma
glucose, 3.9–7.2 mmol/l (70–130 mg/dl).
Table 2 - Primary and secondary outcomes.
Outcomes Control Group (n =87) Intervention Group (n=95) p-value
Primary outcomes
Fasting plasma glucose at the end of hospitalization (mmol/l) 9.8¡2.9 9.1¡2.4 0.21*
Secondary outcomes
Hypoglycemic episodes (no.) 18 (20.7) 17 (17.9) 0.77
Hyperglycemic episodes (no.) 50 (57.5) 47 (49.5) 0.35
Glucose sachets (no.) 9 (10.3) 11 (11.6) 0.97
Number of capillary glycemia assessments 25.2¡17 23.6¡15 0.50
Use of regular insulin 73 (83.9) 40 (42.1) ,0.01
Use of NPH insulin 25 (28.7) 38 (40.0) 0.15
Use of SSI 71 (81.6) 2 (2.1) ,0.01
Infection 3 (3.4) 2 (2.1) 0.92
Coma 0 (0) 1 (1.1) 1.00
Convulsion 0 (0) 1 (1.1) 1.00
Cardiovascular events
Angina 4 (4.6) 2 (2.1) 0.59
Acute myocardial infarction 2 (2.3) 1 (1.1) 0.93
Cardiac surgery 11 (12.6) 10 (10.5) 0.83
Cerebrovascular accident 0 (0) 2 (2.1) 0.51
Length of hospital stay (days) 6 (4–10) 7 (5–10) 0.64
Death 2 (2.3) 3 (3.2) 1.00
Continuous variables are expressed as the means ¡ standard deviation, median, and interquartile range, and categorical variables are expressed as
absolute and relative frequencies (%). The chi-square test and Student’s t test were used. *ANCOVA corrected by baseline plasma glucose. Hypoglycemia:
glycemia ,3.8 mmol/l; hyperglycemia: glycemia .13.8 mmol/l. SSI: sliding scale of insulin.
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team regarding the implementation of a pre-specified treatment
protocol and assessed its possible impact on clinical outcomes.
We found that the incidence of prescribing regular insulin ‘‘as
needed’’ decreased substantially and that the frequency of
capillary glycemia was not different between the groups,
while glycemia and the occurrence of hypoglycemic and
hyperglycemic episodes remained unaffected. Seeking to
identify changes in professional behavior and in clinical
outcomes due to this guidance, we showed that the proposed
intervention changed prescription practice but that there was
Figure 3 - Panel A) Distribution of capillary glycemia (mean¡ SD) during the first week of hospitalization in the groups studied. Panel
B) Distribution of capillary glycemia (mean¡ SD) for each 3-month evaluation in the groups studied. CG: control group (no guidance
of the healthcare team); IG: intervention group (intensive guidance of the medical/nursing staff regarding the protocol).
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no improvement in glycemic control or reduction of hypogly-
cemic or hyperglycemic episodes, hospital stay, or other clinical
outcomes related to diabetes.
Basal-bolus treatment with dose correction using long-
acting, once-daily insulin and short-acting insulin prior to
meals in patients with type 2 diabetes was previously shown
to improve glycemic control and to reduce hospital compli-
cations compared with SSI use in clinical (14) and general
surgery (7) patients. One study of diabetic hospitalized
patients receiving enteral nutrition reported similar glycemic
control in patients treated with a basal-bolus regimen and
those treated with SSI regimens; however, at the end of the
study, 48% of the patients receiving SSI required the addition
of basal insulin (12). However, these favorable results were
obtained in randomized clinical trials in which intensified
glucose control was the primary objective; it is well known
that treatments that are highly effective in trials are not
always effective in real-life care systems.
Guidance by healthcare professionals concerning diabetes
management during hospitalization was effective in chan-
ging prescription practice but did not translate into better
outcomes. Very low doses of regular insulin were pre-
scribed to the intervention groups, as SSI was frequently
omitted from the prescription. We attribute these results to
the intensive guidance program provided to the medical
staff in addition to the supervision of the management by an
endocrinologist. Another study aiming to manage patients
without the use of SSI through systematic education of the
healthcare team showed that training a multidisciplinary
team was effective and safe (15); however, this was a
retrospective study using a historical control group. In a
quasi-experimental study (prior to and after intervention)
(18) that included seminars and the distribution of pocket
guides to a healthcare team in an attempt to increase
adherence to current guidelines on glycemic management of
hospitalized patients, the use of basal-bolus insulin regi-
mens increased from 17% to ,90%, resulting in better
glucose control in most patients; however, most of these
changes were not maintained in the long term. Interestingly,
a small study focusing on improving medical resident
knowledge regarding the management of hyperglycemia in
hospitalized patients also revealed better short-term glucose
control in patients (19).
The results can partially be explained because the policy
of our institution, as many others with similar character-
istics, is the speedy resolution of the underlying cardiac
problem, focusing on solving the main problem during
hospitalization and leaving non-urgent issues for future
resolution at secondary and primary levels. Adherence to
this policy resulted in short-duration hospitalizations.
Additionally, because the treatment was primarily focused
on the underlying cardiac disease, less attention was given
to diabetes (20). Moreover, the high turnover of medical
residents in the unit where the study was conducted could
result in decreased efficiency of the guidance program.
Achieving good glycemic control is a process that may take
longer than the average 6 days for which these patients
remained in the hospital (15).
Another possible explanation for the lack of improvement
in glycemic control is that the glycemic status of our patients
as they arrived at the hospital was not particularly poor
(fasting plasma glucose, 8.5¡3.5 mmol/l); a higher magni-
tude of the effect of the intervention would be expected
when applied to a population with higher potential benefits
(worse glycemic control at admission) compared with a
population with less potential benefits (better glycemic
control at admission) (21). One study that showed good
glucose control over a few days (22) was conducted in
patients with a higher mean plasma glucose at the time of
admission.
Some limitations of this study should be mentioned. A
study conducted at one center in a single non-intensive
inpatient unit may provide results that cannot be fully
reproduced in other scenarios. The relatively short follow-
up time may not allow for the sufficient assessment of the
clinical benefit of improved glycemic control; however, this
situation reflects the real scenario in cardiology hospitaliza-
tion units of a middle-income country. Finally, another
point to be considered is the randomization process. As two
inpatient units with a population of individuals with similar
characteristics were not available, we chose to alternate
treatment in three-month blocks within the same unit,
which may have resulted in interference between the CG
and the IG. However, no carryover effect among these
blocks was observed in the outcomes evaluated.
The clinical experience of glycemic control based on a pre-
established protocol for hospitalized cardiac patients with
diabetes described in the present study shows that the
protocol can be managed in non-intensive care units. Both
strategies were equally effective; however, while guidance
by the healthcare team regarding the glycemic control
protocol resulted in the modification of the therapeutic
strategy, no changes in glycemic control, frequency of
episodes of hypoglycemia and hyperglycemia, or hospita-
lization time were observed. Whether these data indicate a
real negative result in which the use of insulin sliding scales
is less harmful in the short-term hospitalization of diabetic
patients or whether they underscore the need for further
assessment and more intensive intervention programs with
longer follow-ups remains to be investigated.
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